PET/CT measures ENDO-HDR response, may let patients skip chemo

01/30/2013 | AuntMinnie.com (free registration)

PET/CT imaging can determine pathological response in postsurgery patients with stage II and III rectal cancer who underwent short high-dose-rate endorectal brachytherapy prior to surgery, according to results presented at a gastrointestinal cancers meeting. ENDO-HDR may allow patients to avoid chemotherapy before surgery, researchers said. They also hope the method will allow for nonoperative management of many patients.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations